Literature DB >> 20492506

Time-dependent analysis of predisposing factors for the recurrence of hepatocellular carcinoma.

Shouta Iwadou1, Kazuhiro Nouso, Kenji Kuwaki, Yoshiyuki Kobayashi, Shinichiro Nakamura, Hironori Tanaka, Kenji Miyoshi, Hideki Ohnishi, Yasuhiro Miyake, Hidenori Shiraha, Yoshiaki Iwasaki, Yasushi Shiratori, Kazuhide Yamamoto.   

Abstract

BACKGROUND/AIM: There are many reports dealing with the risk factors for hepatocellular carcinoma (HCC) recurrence. However, in most of these reported studies, factors were analysed only at the initial treatment stage, and the predisposing factors for the recurrence during follow-up have not been well studied. The aim of this study is to evaluate the predisposing factors after treatments.
METHODS: Two hundred and seventy-one consecutive HCC patients curatively treated between January 1994 and March 2004 were followed up and analysed. The recurrence rate was estimated by the Kaplan- Meier method and the predisposing factors were evaluated by time-fixed Cox regression analysis and by time-dependent covariate analysis using multiple parameters.
RESULTS: The mean follow-up period was 4.86 years and recurrence was observed in 169 patients (62.4%). The recurrence rates were 27.9, 65.1 and 84.3% at 1, 3 and 5 years respectively. Among the variables determined before treatment, predisposing factors for recurrence were low serum albumin [< or =3.5 g/dl, hazard ratio (HR)=1.47, 95% confidence interval (CI)=1.07-2.01] and multiple tumour number (HR=2.04, 95% CI=1.46-2.84) by time-fixed multivariate analysis. In the time-dependent analysis, six variables with 12 013 plots were examined. The multivariate analysis revealed that high des- gamma-carboxy prothrombin (DCP > or =40 mAU/ml, HR=2.33, 95% CI=1.61-3.39), high alpha-fetoprotein (AFP > or =100 ng/ml, HR=2.01, 95% CI=1.3-3.35) and high alanine aminotransferase (ALT > or = 40 IU/L, HR= 1.52, 95% CI=1.1-2.1) were significant predisposing factors for recurrence.
CONCLUSION: Predisposing factors for the recurrence of HCC after treatment are different from those before treatments and special cautions are required when AFP, DCP or ALT is high during follow-up.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20492506     DOI: 10.1111/j.1478-3231.2010.02252.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  10 in total

1.  Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival.

Authors:  Atsushi Nanashima; Naota Taura; Takafumi Abo; Tatsuki Ichikawa; Ichiro Sakamoto; Takeshi Nagayasu; Kazuhiko Nakao
Journal:  Dig Dis Sci       Date:  2011-06-25       Impact factor: 3.199

2.  Prognosis in the early stages of hepatocellular carcinoma: Predicting outcomes and properly selecting patients for curative options.

Authors:  Kelly W Burak
Journal:  Can J Gastroenterol       Date:  2011-09       Impact factor: 3.522

3.  α-fetoprotein-to-total tumor volume ratio predicts post-operative tumor recurrence in hepatocellular carcinoma.

Authors:  Yun-Hsuan Lee; Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Cheng-Yuan Hsia; Teh-Ia Huo
Journal:  J Gastrointest Surg       Date:  2012-11-28       Impact factor: 3.452

4.  Peritumoral Dilation Radiomics of Gadoxetate Disodium-Enhanced MRI Excellently Predicts Early Recurrence of Hepatocellular Carcinoma without Macrovascular Invasion After Hepatectomy.

Authors:  Huanhuan Chong; Yuda Gong; Xianpan Pan; Aie Liu; Lei Chen; Chun Yang; Mengsu Zeng
Journal:  J Hepatocell Carcinoma       Date:  2021-06-09

5.  Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.

Authors:  Xuqi Sun; Jie Mei; Wenping Lin; Ziliang Yang; Wei Peng; Jinbin Chen; Yaojun Zhang; Li Xu; Minshan Chen
Journal:  BMC Cancer       Date:  2021-07-04       Impact factor: 4.430

6.  Neither MICA Nor DEPDC5 Genetic Polymorphisms Correlate with Hepatocellular Carcinoma Recurrence following Hepatectomy.

Authors:  Takashi Motomura; Yuki Ono; Ken Shirabe; Takasuke Fukuhara; Hideyuki Konishi; Yohei Mano; Takeo Toshima; Shohei Yoshiya; Jun Muto; Toru Ikegami; Tomoharu Yoshizumi; Yoshihiko Maehara
Journal:  HPB Surg       Date:  2012-10-24

7.  Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.

Authors:  Yong Kang Lee; Seung Up Kim; Do Young Kim; Sang Hoon Ahn; Kwang Hun Lee; Do Yun Lee; Kwang-Hyub Han; Chae Yoon Chon; Jun Yong Park
Journal:  BMC Cancer       Date:  2013-01-03       Impact factor: 4.430

8.  Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization.

Authors:  Yuna Kim; Jae Seung Lee; Hye Won Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Seung Up Kim
Journal:  Curr Oncol       Date:  2021-02-21       Impact factor: 3.677

9.  Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients.

Authors:  Sun Young Yim; Ho Soo Chun; Jae Seung Lee; Ji-Hwan Lim; Tae Hyung Kim; Beom Kyung Kim; Seung Up Kim; Jun Yong Park; Sang Hoon Ahn; Gyoung Min Kim; Jong Yun Won; Yeon Seok Seo; Yun Hwan Kim; Soon Ho Um; Do Young Kim
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

10.  Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.

Authors:  Shun Kaneko; Masayuki Kurosaki; Kaoru Tsuchiya; Yutaka Yasui; Yuka Hayakawa; Kento Inada; Yuki Tanaka; Shun Ishido; Sakura Kirino; Koji Yamashita; Tsubasa Nobusawa; Hiroaki Matsumoto; Tatsuya Kakegawa; Mayu Higuchi; Kenta Takaura; Shohei Tanaka; Chiaki Maeyashiki; Nobuharu Tamaki; Yuka Takahashi; Hiroyuki Nakanishi; Namiki Izumi
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.